Skip to content

Trial Summary

A registry study is to evaluate the overall survival, use of subsequent anti-cancer therapy, and the long-term safety of subjects who have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type. Follow-Up will occur every 3 months.

Acronym:

TVEC Registry

ACTRN/NCT /ethics:

NCT02173171

Scientific title:

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

Sponsor / Cooperative group:

Amgen

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeEarly detection, diagnosis, prognosis
Phase-
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2010-04-27
Anticipated End Date2023-01-12

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6410
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusNot Yet Recruiting